The percentage of peripheral FoxP3+ Tregs in vitiligo patients group ranged from 0.6% to 2.1% of CD4+ T cells with a mean of 1.09%  ±  0.96% which was significantly lower than that of control group which ranged from 0.04% to 2.0% with a mean of 1.44%  ± 0.24% (P < 0.05) (Figure 2(b)). This evidence concerns the gene FOXP3 and vitiligo.